Abstract
Introduction

Prostate cancer (PC) is the second most common type of cancer among men in the United States, and it is the second leading cause of cancer death in men. In 2009, an estimated 192
,280 men will be diagnosed with, and 27,360 men will die of PC [1] . There are several therapeutic approaches to treat PC. Surgery (radical prostatectomy) and radiotherapy are therapies with 5-year survival rates greater than 90% [2, 3] . The most significant advance in PC therapy was the observation by Huggins and coworkers [4] that PC is a hormone-dependent disease. In this context, androgen deprivation therapy (ADT) can be achieved using several treatment options. Bilateral orchiectomy has response rates from 50% to 80% [5, 6] [90] , and of the potent differentiating agent phenylbutyrate [91] .
LH-RH antagonists inhibit the LH-RH-R, stopping the production of LH by pituitary gonodatrope cells and, subsequently, of T since, without LH stimulation, Leydig cells in the testis do not synthesize T. Cetrorelix, orgalutran and abarelix belong to this family of compounds. AA are another group of drugs used in ADT. The non-steroidal agonists block T and 5␣-dihydrotestosterone (DHT) from interacting with the cytosolic androgen receptor (AR), which is normally translocated into the nucleus, resulting in cell proliferation and inhibition of apoptosis. Also, in the pituitary gonadotrope may disassociate LH secretion from its negative feedback control, resulting in an elevation of LH and serum T levels. The serum T pre-
The CWR22 heterotransplant was used to investigate the therapeutic efficacy of two histone deacetylase inhibitors, suberoylanilide hydroxamic acid [92] and pyroxamine [93] . The same heterotransplant model was used to test the monoclonal antibody MLN2704 against the prostate specific membrane antigen (PSMA), maytasinoid 1 [94] . In addition, it was used to evaluate the antitumour efficacy of the tamoxifen-quercetin combination [95] , and the tamoxifen-trastuzumab (an anti-Her2/ monoclonal antibody) combination [96] . Bristol-Myers-Squibb has used this heterotransplant to investigate the orally active taxane BMS-275183 [97] . Similarly, the farnesyltransferase inhibitor lonafarnib increases the antitumour activity of docetaxel in combination [98] , and of the oestrogen receptor B inhibitor raloxifene, currently used as an adjuvant in breast cancer [99] . The antitumour efficacy of the selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain, initially named ZD1839 and later gefitinib alone [100] , and in combination with bicalutamide [101] , has been tested using the CWR22 heterotransplant. Recently, a novel series of (2.2.1)-oxabicyclo imide-based AR antagonists have been tested using this heterotransplant [102] , as well as the monoclonal antibody directed against human TMEFF2, a protein highly expressed in PC, alone or conjugated to auristatin E, a known tubulin inhibitor [103] .
The LAPC-4 heterotransplant has been used to investigate the C-17-heteroaryl steroidal CYP17 enzyme inhibitor [104] [108] . Similarly, the PAC-120 heterotransplant, and its androgenindependent variants, were used to evaluate the therapeutic efficacy of mitoxantrone, estramustine phosphate and docetaxel [109] , docetaxel combined with trastuzumab and a Grb2-SH3 ligand named peptidimer-c [110] . [117] . Finally, nuclear magnetic resonance spectroscopy using the CWR22 heterotransplant provides a method to monitor metabolic changes of tumour response to radiation therapy [118] . In this context, the CWR22R heterotransplant has been used to investigate the antitumour activity of the microtubule-depolymerizing agent PC-SPES [121] . Similarly, the EGFR tyrosine-kinase inhibitor gefitinib alone [100] and in combination with bicalutamide [101] have been evaluated using this model, as well as the matriptase inhibitor CVS-3983 [122] , the fungal metabolite FTY720s [123] , the garlic-derived compound S-allyl cysteine [124] , several herbal supplements [125] , and a recombinant humanized monoclonal antibody directed against VEGF (rHu ␣-VEGF) [126] .
and the newer inhibitor 3␤-hydroxy-17-(1H-benzimidazole-1-yl) androsta-5,16-diene, which inhibits not only the enzyme but also the AR, resulting in potent antitumour activity compared to bicatulamide [105]. Also, this heterotransplant has been used to develop more specific 17-␤-estradiol that result in fewer side effects in patients. In this context, the antitumour efficacy of the estradiol analogue, 17␣-estradiol [106] as well as of selenite [107], was investigated. Finally, using this heterotransplant, a series of bifunctional compounds have been synthesized with LH-RH agonists linked to one side and a synthetic ligand to the co-activator binding site of AF-2 domain to the other, resulting in potent LH-RH antagonist activity
Positron emission tomography (PET), a nuclear medicine imaging technique, is used to diagnose, detect and stage primary tumours and metastases, as well as assess the effectiveness of a treatment and monitor disease progression after prostatectomy, radiotherapy or ADT, especially in locoregionally advanced
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Metastases
The LACP-4 tumour serially heterotransplanted into host mice was derived from a metastatic lymph node [27] 
